Achillion Pharmaceuticals is a company engaged in the discovery, development and commercialization of treatments for infectious diseases. It offers a portfolio of orally administered factor D inhibitors, danicopan (ACH-4471) and, second-generation, ACH-5228, for patients with devastating disorders of the complement system.